Wait for the 2-deoxy-D-glucose (2-DG), could get longer. This anti-COVID-19 therapeutic drug 2-deoxy-D-glucose (2-DG) was supposed to be accessible commercially mid-June, on the other hand, the Dr Reddy’s Laboratories (DRL), Hyderabad, has no definitive date for this but.
When will it be accessible commercially?
In an e mail response to TheSpuzz Online query, DRL’s ccompany spokesperson says: “Dr Reddy’s has not announced the commercial launch of 2-DG yet. We will continue to share updates as they become available.”
Sharing more about the a lot awaited indigenous therapy for COVID-19, the enterprise spokesperson adds, “2-DG is an oral antiviral drug that can be administered only upon prescription to hospitalised moderate to severe COVID-19 patients as adjunct (add on) therapy, alongside the existing standard of care. Details of the clinical trials and emergency use approval were released by the DRDO (Defence Research and Development Organisation) on May 8, 2021.”
Role of DRL
The 2-DG has, according to DRDO, been jointly created by Institute of Nuclear Medicine and Allied Sciences (INMAS), and Dr Reddy’s Laboratories (DRL), Hyderabad.
This drug was officially released by defence minister Rajnath Singh last month.
During the surge in COVID-19 positive instances, on May 25, 2021, in an e mail response to a query about the availability of the miracle drug, the DRL enterprise spokesperson had mentioned, “commercial launch and supply of 2DG to major Government and private hospitals is expected to commence in mid-June.”
Similar information and facts was also shared on social media platforms also.
As reported earlier, the official spokesperson of Dr Reddy’s in an e mail had described that “2-DG is an oral drug. And this has to be administered upon prescription to the hospitalised moderate to severe COVID-19 patients. It will be in addition to the existing standard of care.”
Availability at the pharmacies
During the surge in instances, these searching for the miracle drug have been asked to be in touch with DRL which was sending straight to the hospitals on presentation of the prescriptions.
Once the drug is accessible commercially it will be supplied to the hospitals.
Will it be accessible OTC & pricing?
There is no clarity on this so far. The DRL spokesperson had told TheSpuzz Online that the pricing would be very affordable and will be accessible to as several patients as attainable.
Debate more than the efficacy
DRDO official told TheSpuzz Online that DRL was the development companion with DRDO in the study on COVID-19 patients. DRL has been a lengthy -standing sector companion of DRDO for 2-DG clinical applications considering that 2004.
This drug has effectively completed the Phase-3 clinical trials for radiotherapy of brain tumor patients.
As reported earlier, no other institute was involved in the trials of this drug.
The story so far …
The official statement issued by the Ministry of Defence on May 8, 2021, mentioned that the trials for the drug had began last April in the course of the very first wave of the worldwide pandemic.
In an official statement issued by the Ministry of Defence (May 8, 2021), this drug has been jointly created and made by DRDO and DRL.
The statement mentioned that the drug has undergone clinical trials, in which the scientists from INMAS had carried out experiments with the assistance of Centre for Cellular and Molecular Biology based in Hyderabad. And the outcomes indicated that there was a more quickly recovery of hospitalized patients and it also decreased dependency on supplemental oxygen.